Compare SIBN & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIBN | QURE |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.7M | 663.4M |
| IPO Year | 2018 | 2013 |
| Metric | SIBN | QURE |
|---|---|---|
| Price | $13.83 | $17.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 14 |
| Target Price | $24.13 | ★ $45.42 |
| AVG Volume (30 Days) | 512.4K | ★ 4.7M |
| Earning Date | 05-14-2026 | 06-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.33 | 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,301,000.00 | $13,107,000.00 |
| Revenue This Year | $16.89 | $126.14 |
| Revenue Next Year | $14.95 | $395.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.53 | N/A |
| 52 Week Low | $12.50 | $7.76 |
| 52 Week High | $21.89 | $71.50 |
| Indicator | SIBN | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 37.16 | 46.00 |
| Support Level | N/A | $13.29 |
| Resistance Level | $17.05 | $26.84 |
| Average True Range (ATR) | 0.75 | 2.09 |
| MACD | -0.09 | 0.25 |
| Stochastic Oscillator | 21.39 | 49.94 |
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.